IBRX stock forecast, quote, news & analysis
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases... Show more
ImmunityBio (IBRX) Stock Analysis: Anktiva's Global Launch Momentum Anchors a High-Growth Biotech Story
Key Takeaways
- ImmunityBio is a commercial-stage biotechnology company whose lead product, Anktiva, anchors both its revenue and its growth narrative.
- Net product revenue grew roughly 700% in 2025 to $113 million, with sequential quarterly growth continuing into 2026.
- Anktiva's regulatory footprint has expanded to 34 countries across five jurisdictions, extending beyond its original bladder cancer indication.
- Despite meaningful short-term volatility, the stock's net move over the past 30 days has been relatively modest.
- The company remains unprofitable and carries a stockholders' deficit, making cash position and future funding central watch items.
- For additional detail on valuation, results, and projections, explore the Price Targets, Earnings, and Forecast pages.
- To discover algorithmic strategies across the market, visit the Trending AI Robots page.
Current Market Snapshot
ImmunityBio shares have traded within a wide range over the trailing year, between roughly $1.83 and $11.00, reflecting the elevated volatility typical of early-stage commercial biotechs. In recent sessions the stock has fluctuated between the upper single digits and just above $10 as investors weigh rapid revenue growth against continued operating losses. Over the most recent 30-day period, the stock's net change has been comparatively subdued relative to its longer-term run, even as intraday swings have remained pronounced. This pattern points to a market that is pricing in both the promise of Anktiva's expansion and the financial execution risks that accompany a company still scaling toward profitability.
ImmunityBio (IBRX) Business Overview and Competitive Position
ImmunityBio develops and commercializes next-generation immunotherapies designed to activate both the innate and adaptive arms of the immune system. Its central platform, the Cancer BioShield, is anchored by Anktiva (nogapendekin alfa inbakicept), an interleukin-15 (IL-15) receptor superagonist antibody-cytokine fusion protein engineered to stimulate natural killer cells, cytotoxic T cells, and memory T cells.
In the United States, Anktiva is approved in combination with Bacillus Calmette-Guérin (BCG) for adults with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors. That indication forms the current commercial base. Beyond bladder cancer, the company is pursuing label expansion into settings such as non-small cell lung cancer and additional solid and liquid tumors, positioning Anktiva as a platform rather than a single-use therapy. Investors follow IBRX closely because its story hinges on a single commercial asset whose adoption trajectory and regulatory milestones can drive outsized moves in either direction.
Recent Developments Driving IBRX
Several verified developments have shaped investor sentiment. The company reported net product revenue of approximately $44.2 million for the first quarter of 2026, up 168% year over year and 15% sequentially, and followed with second-quarter 2026 net product revenue of roughly $50.7 million, up 92% year over year. This extended a streak of sequential quarterly growth since Anktiva's commercial launch.
On the regulatory front, Anktiva's footprint has expanded rapidly. The European Commission granted conditional marketing authorization in early 2026, Saudi Arabia's SFDA granted conditional accelerated approval in metastatic non-small cell lung cancer, and the United Arab Emirates issued marketing authorizations spanning both NMIBC and NSCLC. The FDA also accepted for review a supplemental Biologics License Application for Anktiva in BCG-unresponsive NMIBC with papillary tumors without CIS, with a PDUFA target action date of January 6, 2027. Meanwhile, the pivotal BCG-naïve trial reached full enrollment, with a supplemental filing targeted for 2026. These milestones support the growth narrative, though non-cash charges tied to a related-party convertible note and warrant liabilities continue to weigh on reported net losses.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of algorithmic trading strategies drawn from a broader universe of hundreds of AI-powered bots that trade thousands of tickers. Only the top-performing and most relevant bots are featured in this section, giving traders a focused view of strategies currently attracting attention. These robots differ in trading style, holding timeframe, and performance metrics, so the page serves as a starting point for comparing approaches rather than a one-size-fits-all recommendation. Exploring the section can help investors understand how quantitative, rules-based systems are navigating conditions across the market, including volatile biotech names.
2026 Outlook and What Investors Should Watch
Looking ahead, investors are likely to focus on several concrete drivers. Continued Anktiva adoption among U.S. urologists and the pace of international launches in Europe and the Middle East will be central to the revenue trajectory. Regulatory decisions, including the January 2027 PDUFA date for the papillary-tumor indication and a planned 2026 filing from the BCG-naïve trial, represent key catalysts. Cost trends matter as well: management has indicated that cost of sales should rise as pre-launch inventory is depleted, and operating expenses are expected to increase alongside label-expansion and commercialization efforts.
Balance-sheet strength remains a critical watch item. The company ended the first quarter of 2026 with about $381 million in cash and marketable securities, but it carries a significant stockholders' deficit and substantial liabilities tied to a related-party convertible note and a revenue interest liability. Management has stated that existing cash, product sales, and potential equity offerings are expected to fund operations for at least the next 12 months, while also noting substantial doubt about long-term viability without additional funding. These factors, rather than short-term price swings, are likely to define the investment debate around IBRX through 2026.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Aroon Indicator for IBRX shows an upward move is likely
IBRX's Aroon Indicator triggered a bullish signal on October 14, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 123 similar instances where the Aroon Indicator showed a similar pattern. In 117 of the 123 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 61 of 68 cases where IBRX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
Following a +12.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBRX advanced for three days, in 210 of 242 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
IBRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day RSI Indicator for IBRX moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In 18 of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IBRX as a result. In 79 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
The Moving Average Convergence Divergence Histogram (MACD) for IBRX turned negative on October 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In 43 of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
IBRX moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for IBRX crossed bearishly below the 50-day moving average on October 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-8.395) is normal, around the industry mean (3.154). P/E Ratio (-8.726) is within average values for comparable stocks, (-1.071). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.299) among similar stocks. P/S Ratio (47.847) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. IBRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IBRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a producer of cancer treatment products
Industry Biotechnology